You can help us put a stop to online scams before they grow too big and end up ruining thousands of lives. A scam is a scam, doesn’t matter if it’s big or small. Now that this is out of the way, let’s get started with the review.
David Johnston CFO is reportedly one of the top scammers in the biotechnology and life science sectors, according to many investigations. Come, I’ll tell you the whole tale of this industrialist’s fraud.
David Johnston CFO: A Brief Overview
The Massachusetts-based company DBJ Consulting LLC was established in 2019 by David Johnston, a seasoned financial expert who has held CFO positions in the past with biotechnology and life sciences companies. Smaller, newly established life sciences companies are the company’s specialty.
Since they have low resources, tiny teams of less than ten employees, and an online presence, these enterprises frequently struggle. The recruitment of a full-time Chief Financial Officer, CFO presents them with a difficult challenge.
We look at 34 different data points when analyzing and rating online money-earning opportunities. Once the research on these data points is submitted, expert contributors reach out to the company’s customers and associates to get more insight into their operation. Finally, all the collected information is presented in the form of this expert review.
All the data is extracted from publicly available information and the sources are given in the transparency section at the bottom of every report.
These reports are made possible by the collective efforts of contributors like you. If you would like to become a contributor then contact us here.
To help with this, David Johnston CFO promotes his assistance as a part-time CFO, allegedly helping these companies with his financial expertise without having to hire a full-time executive.
David Johnston CFO believes in the growing number of part-time C-level executives, which is likely why he appears to be satisfied in his role as a fractional CFO.
He emphasizes his ability to keep a work-life balance, possibly avoiding burnout, and maintaining long-term productivity when arguing that this trend is favorable for both businesses and executives.
A lack of constant interest in one position may also be hinted at by the fact that working for multiple companies may be perceived as a strategy for tackling routine.
I can therefore declare that all the assertions of David Johnston CFO are untrue. Furthermore, I have a ton of evidence supporting his fraudulent behavior. Come on, let’s talk about it. You may follow the mentioned links to learn more about his fake personality:
- https://www.linkedin.com/in/david-johnston-cfo-43627290
- https://davidjohnstoncfo.com/
- https://www.crunchbase.com/person/david-johnston-cfo
Allegations against David Johnston CFO
Three former executives connected to the Massachusetts-based biotech company AVEO Pharmaceuticals Inc. as well as the corporation have been charged with fraud, according to the Securities and Exchange Commission (SEC).
The accusations derive from claims that the business deceived investors about its attempts to win the Food and Drug Administration’s (FDA) approval for its lead experimental medication meant to treat kidney cancer.
Complaints by the SEC centered on the claim that David Johnston CFO, of AVEO Pharmaceuticals, misled investors by omitting important information from their public statements.
In particular, the business concealed important FDA worries regarding the medicine Tivozanib, also known as, patient death rates throughout the initial clinical study.
It became known that the FDA staff had suggested an additional investigation to address these worries. The company’s public discussions with investors, however, did not include this important data.
The FDA recommended a new clinical trial a few months later, and this advice was made public. This information caused a huge decrease in the company’s stock price, which fell by 31%.
It was significant to note that AVEO Pharmaceuticals did not carry out the extra clinical trial that the FDA had asked, notwithstanding their recommendation. The FDA also declined to approve Tivozanib in the future.
AVEO Pharmaceuticals has consented to pay a $4 million fine in response to these accusations in order to resolve the SEC’s complaints. It’s critical to stress that the corporation has made no admissions of guilt or misconduct in connection with this settlement.
Three former AVEO Pharmaceuticals officers, including CEO Tuan Ha-Ngoc, David Johnston CFO, and CMO William Slichenmyer, will still be the target of legal action from the SEC.
AVEO Pharmaceuticals has been charged by the SEC with engaging in fraudulent actions by concealing crucial information concerning FDA concerns regarding its experimental medicine, which caused the price of the company’s stock to drop sharply. Although the corporation has consented to pay a sizable fine, the legal actions against three previous executives are still pending.
What were the complaints of the SEC?
- A research study for Tivozanib was specifically advised by the FDA staff during a conference in May 2012, but AVEO did not disclose this information when it raised $53 million in an initial offering of the company’s stock in January 2013.
- The FDA’s concerns were severe, and AVEO and its officers realized that it would be costly and time-consuming to conduct an additional clinical trial. AVEO even went so far as to plan a follow-up study and present its plans to the FDA, but the study was never carried out.
- AVEO and its officers implied in corporate communications that they expected to satisfy the FDA by delivering fresh evaluations of the information obtained during the last clinical trial. In doing so, AVEO disregarded advice from FDA personnel to undertake a second clinical trial and their level of worry about how Tivozanib may affect patient survival.
- The FDA staff’s advice for a further clinical trial was not disclosed in the press release or public papers that Ha-Ngoc and Johnston knowingly approved and certified.
- During investor conferences, Johnston also made statements to the public in which he implied that the FDA officials had just requested an explanation of the persistent results. Actually, a second trial had been suggested by the FDA personnel.
- In a conference call with investors, Slichenmyer gave incorrect information about his ability to “speculate” concerning what the FDA “might be thinking” and “might want [AVEO] to do in the future.” He was aware that the FDA personnel had advocated for a further trial.
The SEC’s allegations accusations AVEO, Ha-Ngoc, Johnston, and Slichenmyer of violating Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 thereunder, AVEO with violating Exchange Act Section 13(a) and Rules 12b-20, 13a-1, 13a-11, and 13a-13 thereunder, and Ha-Ngoc and Johnston with violating Exchange Act Rule 13a-14.
Court approval is required for the AVEO settlement. The SEC is requesting that Ha-Ngoc, Johnston, and Slichenmyer be subject to officer-and-director bars, and disgorgement, along with interest and penalties.
The Market Abuse Unit of the Enforcement Division’s Boston Regional Office conducted the SEC’s investigation under the direction of Susan Cooke Anderson and Michele T. Perillo. Ms. Anderson and Rachel E. Hershfang will be in charge of the SEC’s legal defense.
The Securities and Exchange Commission (SEC) filed accusations against David Johnston CFO in a federal jury trial that took place in a U.S. District Court in Boston. The jury unanimously found Johnston responsible for the offenses.
These charges centered around claims of fraudulent behavior, specifically making false statements or substantial inaccuracies and filing records to the Securities and Exchange Commission that contained falsehoods. David Johnston CFO allegedly made money off of these deeds, according to another claim.
Although prior rulings had not imposed this restriction, the original lawsuit from the SEC attempted to prevent David Johnston CFO, and other officials from holding positions as officers or directors of publicly traded firms.
According to the SEC’s lawsuit, Aveo carried out a secondary offering in January of the subsequent year and raised $53.8 million.
Before these developments, a consent judgment was struck against the previous Aveo CEO Tuan Ha-Ngoc in December of the previous year, and he was required to pay a $80,000 civil penalty. William Slichenmyer, the organization’s previous CMO, was also penalized with a $50,000 fine in March of the same year.
All the details that I mentioned about the case of David Johnston CFO, discloses the fake personality of David Johnston CFO. Moving further I would like to share another article posted against the illegal actions of David Johnston CFO.
David Johnston CFO obviously didn’t give a damn about any of that. When contacted by the media, ImmunoGen, his employment at the time, stated that since the situation was unrelated to them, they were unable to respond.
David Johnston CFO, resigned, but they maintained him in that position for the remaining months of the year.
In the end, it was a lawsuit. Several biotech companies have a history of misleading investors about their interactions with the FDA, which has recently raised concerns from the FDA.
SEC even brought up the problem by publicly cautioning biopharma. However, the FDA is required by law to keep quiet.
According to the information in the report, ImmunoGen’s former CFO was David Johnston. He was forced to resign from that post, nonetheless, after the SEC found him guilty of defrauding investors and engaging in fraud.
Even David Johnston’s CFO was described by SEC lawyer Eric Fornii as a sleazy used car dealer. The lawyer emphasized that he had plans to deceive biotech investors by falsely representing them that the FDA had a favorable opinion on Tivo.
While he acknowledged that the FDA had some reservations, he compared it to a salesperson who told a customer that the vehicle’s engine might make some noises without disclosing that the customer actually needed a completely new engine.
David Johnston CFO was found responsible for securities by the jury.
Where is CFO David Johnston right now?
David Johnston CFO, as per his most recent updates and internet profiles, has started DBJ Consulting. He currently holds the positions of Biotechnology Financial Executive and Fractional CFO.
After nine years of service and after being found guilty of fraud, he was forced to depart ImmunoGen, Inc. He spent six years prior to that serving as CFO at Aveo.
Washington & Lee University awarded David Johnston CFO with a Bachelor of Science in Commerce, and the University of Michigan’s Stephen M. Ross School of Business awarded him with an MBA.
Conclusion
My entire study points to charges against David Johnston, a CFO in the life sciences industry, that raise questions about his integrity. Your interpretation of his conduct in this area, which is related to human welfare, suggests that he is abusing people for personal benefit by engaging in harmful behaviors.
Making definite judgments about his character or behavior, however, can be inappropriate and perhaps unfair without knowing the specifics of the accusations and any pending legal processes. Legal issues should be assessed using the law and due process.
I can give another example of a person like David Johnston CFO, the person who is involved in pharmaceutical fraud cases & exploiting the human population for their scams:
Tom Gory- Tom Gorgy – $39,000 PharmaFraud & Burying News – Gripeo
In the end, I have discovered a few links connected to the fraud of David Johnston CFO, which are mentioned below:
- https://www.genengnews.com/news/aveo-agrees-to-4m-penalty-to-settle-sec-fraud-charges/
- https://www.reuters.com/article/securities-aveo-idUSL1N2JX2NT
- https://www.lexology.com/library/detail.aspx?g=f92f95fa-8531-4f21-9c9e-931c7de49d7f
- https://www.biopharmadive.com/news/cambridge-based-aveo-settles-fraud-charges-with-sec-for-4-million/416488/
- https://casetext.com/case/us-sec-exch-commn-v-johnston
- https://www.fiercebiotech.com/r-d/aveo-hit-4m-sec-fraud-penalty-feds-set-out-to-bar-former-execs-for-deception
- https://www.cooley.com/news/insight/2016/2016-04-06-life-sciences-company-hit-with-4-million-sec-penalty
- https://www.policymed.com/2016/04/aveo-pharmaceuticals-to-pay-4-million-to-settle-sec-charges.html
- https://caselaw.findlaw.com/court/us-1st-circuit/2108312.html
